ZINFORO®: Optimising outcomes for patients with cSSTI1-6,*
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
*There is no experience with ZINFORO® in the treatment of cSSTI in the following patient groups: The immunocompromised; patients with severe sepsis/septic shock, necrotising fasciitis, perirectal abscess and patients with third-degree and extensive burns.
There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.1
†Potency has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to antibiotics in vitro. In vitro activity does not always correlate with clinical efficacy.
cSSTI, complicated skin and soft tissue infection; MoA, mechanism of action; MRSA, methicillin-resistant Staphylococcus aureus.
References:
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.